Booting Earth Optimization System
Thank you for your patience. Your civilization is very important to us.
Ustekinumab
Treatment for Crohn's Disease
Typical Dosage: Initial IV dose based on weight (e.g., 260, 390, or 520mg), then 90 mg SC every 8 weeks
Effectiveness
72%
Safety Score
50%
Clinical Trials
78
Participants
8K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
50
DangerousModerateSafe
Treatment Details
Dosage Range
Initial IV dose based on weight (e.g., 260, 390, or 520mg), then 90 mg SC every 8 weeks
Time to Effect
4-8 weeks
Treatment Duration
lifetime
Evidence Quality
HIGHNumber Needed to Treat (NNT)
6(Treat 6 patients to see 1 additional successful outcome)
Number Needed to Harm (NNH)
75(Treat 75 patients to see 1 additional serious adverse event)
Confidence Score
88%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$32,000
Monitoring:$1,150
Side Effect Mgmt:$500
Total Annual:$33,650
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
EXCELLENTICER
$40,000/QALY
QALYs Gained
0.07
Outcome-Based Costs
Cost per Responder
$61,182
Cost per Remission
$112,167
WARNING: LIMITED TRIALS AVAILABLE
You can search for trials, but you probably can't join any because the 1% Treaty hasn't passed yet. Most trials are severely limited by lack of funding and bureaucratic barriers. Help change this!
Active Clinical Trials
6 active trials recruiting for Ustekinumab in Crohn's Disease
A Study of Vedolizumab Intravenous (IV) and Adalimumab or Vedolizumab and Ustekinumab in Adults With Crohn's Disease
NCT06045754RECRUITINGPHASE4
100 participants
INTERVENTIONAL
Dothan, United States +53 more
Started: Apr 18, 2024
USTekinumab in Fistulising Perianal Crohn's Disease (USTAP)
NCT04496063ACTIVE NOT RECRUITINGPHASE4
33 participants
INTERVENTIONAL
Rennes, France +19 more
Started: Nov 16, 2020
Efficacy and Safety of Dual-targeted Therapy With Upadacitinib and Ustekinumab Versus Intensified Ustekinumab Therapy in Crohn's Disease
NCT06520397RECRUITINGPHASE4
214 participants
INTERVENTIONAL
Guangzhou, China
Started: Jul 15, 2024
Study Comparing Intravenous (IV)/Subcutaneous (SC) Risankizumab to IV/SC Ustekinumab to Assess Change in Crohn's Disease Activity Index (CDAI) in Adult Participants With Moderate to Severe Crohn's Disease (CD)
NCT04524611ACTIVE NOT RECRUITINGPHASE3
527 participants
INTERVENTIONAL
Chandler, United States +299 more
Started: Sep 30, 2020
An Open-Label Extension and Long-term Efficacy and Safety Monitoring Study of Patients with Crohn's Disease Previously Included in the Loss of RESponse to Ustekinumab Treated by Dose Escalation Study
NCT05299931ACTIVE NOT RECRUITINGPHASE3
108 participants
INTERVENTIONAL
Zaventem, Belgium
Started: Sep 10, 2021
An Open-Label, Proof of Consent Study of Vorinostat for the Treatment of Mdoerate-to-Severe Crohn s Disease and Maintenance Therapy With Ustekinumab
NCT03167437RECRUITINGPHASE1, PHASE2
35 participants
INTERVENTIONAL
Bethesda, United States
Started: Oct 30, 2017
Completed Clinical Trials
11 completed trials for Ustekinumab in Crohn's Disease
A Study of Ustekinumab Treatment in Children With Crohn's Disease
NCT05242458COMPLETED
545 participants
OBSERVATIONAL
Burlington, United States
Started: Mar 21, 2022
A Study of Ustekinumab (STELARA) in Chinese Participants With Moderately to Severely Active Crohn's Disease
NCT05029921COMPLETEDPHASE4
182 participants
INTERVENTIONAL
Beijing, China +28 more
Started: Dec 10, 2021
Assessment on the Deep Remission Rate and Its Influencing Factors of Individualized Ustekinumab Therapy in Patients With Crohn's Disease
NCT07600255COMPLETED
156 participants
OBSERVATIONAL
Wenzhou, China
Started: Jan 1, 2021
Post-Marketing Surveillance for Crohn's Disease Participants Treated With Stelara (Ustekinumab)
NCT03942120COMPLETED
685 participants
OBSERVATIONAL
Busan, South Korea +42 more
Started: Apr 8, 2019
A Retrospective Observational Study of Ustekinumab Among Bio-naive Participants With Crohn's Disease in China
NCT06082986COMPLETED
200 participants
OBSERVATIONAL
Hangzhou, China +2 more
Started: Oct 9, 2023
Loss of RESponse to Ustekinumab Treated by Dose Escalation
NCT04245215COMPLETEDPHASE3
108 participants
INTERVENTIONAL
Zaventem, Belgium
Started: Mar 11, 2020
An Analysis of the Relationship Between the Genetic Polymorphisms of Interleukin 12 Receptor Subunit Beta 1 and Crohn's Disease in Chinese Patients
NCT07057856COMPLETED
866 participants
OBSERVATIONAL
Wenzhou, China
Started: Jan 1, 2018
Prospective Observational Study on Ustekinumab (Stelara) Assessing Efficacy and Healthcare Resource Utilization in Crohn's Disease
NCT03495973COMPLETED
114 participants
OBSERVATIONAL
Örebro, Sweden
Started: Oct 25, 2017
A Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease
NCT03926130COMPLETEDPHASE3
1.16K participants
INTERVENTIONAL
Birmingham, United States +579 more
Started: Jul 23, 2019
A Pharmacokinetic Study of Ustekinumab in Pediatric Subjects With Moderately to Severely Active Crohn's Disease
NCT02968108COMPLETEDPHASE1
45 participants
INTERVENTIONAL
Los Angeles, United States +25 more
Started: Jan 18, 2017
Study of Treat to Target Versus Routine Care Maintenance Strategies in Crohn's Disease Patients Treated With Ustekinumab
NCT03107793COMPLETEDPHASE3
500 participants
INTERVENTIONAL
Antwerp, Belgium +106 more
Started: Apr 19, 2017
Showing 20 of 89 total trials